Q1 2025 Financial Results
Grifols first quarter 2025 results.
Showing 228 search results
Grifols celebrates 25th anniversary of its Diagnostic R&D center in Bizkaia, a key driver of its sector leadership
Grifols receives FDA clearance of IND application for Phase 2 trial of immunoglobulin drops for dry eye disease
Grifols delivers strong results across the board, increasing revenues by 7.4%, Adj EBITDA by 14.2% and improving free cash flow by EUR 209m
Grifols partners with IBL International to develop advanced biomarker panels for unique clinical diagnostics platform
Grifols appoints Montse Ribas as Chief Communications and Reputation Officer to strengthen the company's global reputation
Grifols and Inpeco joining forces to deliver transfusion medicine ‘lab of the future’
Publications
Links to our latest financial and sustainability reports and other recent publications.
Financial Report
Explore our last financial and earnings report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.